cancer drug pricing

Sharp price increases for cancer drugs
Sharp price increases for cancer drugsA majority of oncology drugs—particularly older cancer drugs—had price hikes in 2015, according to a study. Plus, Ariad Pharmaceuticals raised the price of its chronic myeloid leukemia (CML) drug ponatinib (Iclusig) for the fourth time this year to around $199,000 a year, according to The Street.
Patients demand access to investigational therapiesExpanded access or “compassionate use” programs allow patients to use investigational treatments, medical devices, or tests, before they have received FDA approval.
CVS, Express Scripts plan value-based drug pricingThe approaches reflect a growing number of initiatives meant to tie drug prices to value. Find out more.
Oncologists not prescribing expensive cancer drugsIn the latest controversy over the high cost of certain prescription medications, a recent Reuters article said that more oncologists won’t prescribe expensive drugs.
Oncology drugs in the pipelineSeveral new drugs hold promise, but cost is a top concern.